Are you getting the best rate from your broker?
Compare your broker's rates now to find out if you can save money

Choose your broker below
Welcome to Dividend.com. Please help us personalize your experience.

Select the one that best describes you
Dividend logo

The major pharmaceutical companies are facing quite a predicament. Billions of dollars worth of patent-protected drugs have already gone or are preparing to go generic over the next few years. Dubbed the “patent cliff”, the loss of these blockbusters and other major money-making drugs for the largest pharmaceutical companies is enough to make any investor cringe. For dividend investors, it’s especially troublesome as some of these drugs have been the driving force behind Big Pharma’s status as dividend safe havens.

Rather than resignedly driving over the cliff, Big Pharma has at least begun to pump the brakes and look for alternatives. As a result, Big Pharma has found itself diving head first into biotech manufacturers and their lucrative cures for rare diseases.

Except, it turns out that biotech may not be the panacea they hoped for. Regulation and public scorn could crimp the ability of the biotechs – and correspondingly Big Pharma – to charge an arm and a leg for the medications.

To read the Full Story, Go Premium or Log In

Popular Articles

Premium Trade%20war
News

The Market Wrap for September 20: Trade Continues to Ease

With economic data being relatively good and the earnings season pretty much over, traders have...

Dividend Investing Ideas Center

Dividend History of the Consumer Staples Sector

Consumer staples have long been regarded as an essential component of any well diversified...

Premium Volatile%20markets
News

Are We Slipping Into the Abyss? The Markets Think So

Investors are certainly facing an interesting paradox these days.

Economic conditions are some of...